Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes (Q38189114)

30 August 2017

title

Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes (English)

1 reference

30 August 2017

1 reference

Stephanie A Stein

1

1 reference

30 August 2017

Elizabeth M Lamos

series ordinal

2

1 reference

30 August 2017

Stephen N Davis

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

19 February 2014

1 reference

Expert Opinion on Drug Metabolism & Toxicology

30 August 2017

published in

1 reference

30 August 2017

volume

10

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

599-608

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Vildagliptin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17425255.2014.889683

10.1517/17425255.2014.889683

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference